Japan plans to revise its guidelines on the drone delivery of medicines later this month, which would mark the first revision since they were established two years ago. Service providers are closely watching how they will be revised, with calls…
HOME > COLUMN
COLUMN
- Pharmaceutical Companies in Japan Cross Cultural Boundaries to Retain and Hire the Best and the Brightest
March 18, 2013
- Ichi-go Ichi-e - “One Opportunity, One Encounter”
February 20, 2013
- Our Habits Are the Nuts and Bolts of Our Destiny
January 22, 2013
- What Are Japanese Pharmaceutical Candidates Thinking?
December 18, 2012
- Mid-Level Managers Seek More Guidance and Global Opportunities from Their Senior Management at Japan’s Multinational Pharmaceutical Companies
November 19, 2012
- Leading from Afar
October 22, 2012
- “Make Up Your Own Mind? What It Takes to Win Over Top-Tier Japanese Employees”
September 18, 2012
- Our Habits Determine Our Success
August 8, 2012
- Marketing Is More than a Pen and a Tissue Box
July 9, 2012
- Science without Works Is Dead
June 4, 2012
- Social Networking in Japan’s Pharmaceutical Industry
May 1, 2012
- The Eight Characteristics of a Great Leader
April 2, 2012
- Maurer’s Healthcare Insight (143)
March 26, 2012
- Maurer’s Healthcare Insight (142)
February 27, 2012
- Maurer’s Healthcare Insight (141)
January 30, 2012
- Maurer’s Healthcare Insight (140)
December 26, 2011
- Maurer’s Healthcare Insight (139)
December 12, 2011
- Maurer’s Healthcare Insight (138)
November 21, 2011
- Maurer’s Healthcare Insight(137)
October 17, 2011
- Maurer’s Healthcare Insight (136)
September 12, 2011
ページ
The healthcare supply chain in Japan, as in all major markets, consists of biopharmaceutical manufacturers selling to wholesalers who in turn sell to hospitals, clinics, and pharmacies, where the drugs are finally dispensed to patients. Each party ideally contributes value…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…